IBAB Ion Beam Applications SA

IBA's 30 Years of Leadership

Louvain-la-Neuve - 6 September 2016 - IBA (Ion Beam Applications S.A.), the world leader in proton therapy solutions for cancer treatment, is celebrating its 30^th anniversary. To mark the occasion, over 600 guests are expected tonight in Louvain-la-Neuve. Key company representatives, namely Yves Jongen - founder and Chief Research Officer, Olivier Legrain - CEO, and Pierre Mottet - Chairman of the Board, will use this festive and music-filled backdrop to revisit the reasons for the Company's success and talk about the opportunities that lie ahead.

An internal event will also take place to thank employees for their work, commitment and professionalism.

30 years marked by ambition, passion and success...

IBA's story begins in the early 80s when Yves Jongen sets his sights on making cyclotrons available for medical purposes. Under the aegis of UCL he assembled a team that shared his passion for this ambitious project. Pierre Mottet was among them.

The whole team shares a vision and values: the passion, ambition and desire to preserve IBA's Belgian roots, of which they are proud, both in terms of its shareholders and the creation of high-quality jobs.

In its first year, IBA sold an initial four cyclotrons and experienced explosive growth, resulting in the number of employees tripling. That was the beginning of the success story.

Today, with approximately 50% of the proton therapy market, IBA is still the world leader in solutions for proton therapy, the most advanced form of radiotherapy for treating cancer currently available. Specifically, the technology makes it possible to target a tumour with unrivalled precision without damaging the surrounding healthy tissue. IBA also develops dosimetry solutions in radiotherapy and radiology, as well as particle accelerators for medical and industrial applications.

... and a bright future ahead

IBA's success continues. The business has experienced accelerated growth and sales in proton therapy over the past 24 months, evidence of the Belgian Company's dynamism and of the quality of its products and services, bringing worldwide recognition and still more opportunities for growth.

• The clinical benefits of proton therapy are increasingly acknowledged. While proton therapy today represents less than 1% of all radiotherapy treatments, studies estimate that over 17% of patients receiving radiotherapy would benefit from being treated with proton therapy. A large number of clinical studies are currently ongoing and their results could open a new era for proton therapy treatment.
   
• Proton therapy is becoming more and more accessible to a growing number of patients throughout the world. IBA has invested substantial resources in researching and developing new approaches so as to minimise the cost of proton therapy and make it more accessible to all cancer patients. In line with this commitment, Proteus^®ONE is a compact, single-room treatment solution that is more affordable while also being easier to install, operate and finance. Proteus^®ONE also offers the latest advance in proton therapy: image-guided therapy.
   
• IBA continues to deploy technological solutions offering clinical added value, and maintains its unrivalled position as an innovator in proton therapy technology. For example: Pencil Beam Scanning (PBS) technology makes it possible to precisely pattern the dose in complex volumes and, in imaging, CBCT technology allows imaging to be conducted directly in the treatment room to enable better positioning of the patient. Supporting this, gramma cameras help verify the beam range.

Yves Jongen, founder and Chief Research Officer, said: "Our initial objective was to develop a technology to improve cancer treatment and create high-quality employment in Belgium through an ambitious and innovative project. Now, 30 years later, our commitment has remained the same and we are pursuing innovation by identifying new technological opportunities that will allow us to provide increasingly high standards while reducing treatment costs".

Olivier Legrain, Chief Executive Officer of IBA, added: "More than ever we believe in IBA's mission to protect, improve and save lives. Our goal today is to make proton therapy accessible to greater numbers of patients, and we will achieve this thanks to the passion, energy and skill of IBA's employees".

Pierre Mottet, Chairman of the Board, concluded: "From the beginning, IBA's DNA has made the difference. We are proud of this company which creates, innovates, stimulates and passionately believes in its employees; a company that is committed to helping improve patients' quality of life, that is committed to its clients, employees, shareholders, the community and, more broadly, to current and future generations across the world."

***End***

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com

For more information, please contact:

IBA

Thomas Ralet
Vice President of Corporate Communication
+32 10 47 58 90
communication@iba-group.com

Whyte Corporate Affairs
Marine Catlin
+32 2 738 06 32
mc@whyte.be

Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024

Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024